A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : LA / lipoprotein apheresis

[Related PubMed/MEDLINE]
Total Number of Papers: 92
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   LA  (>> Co-occurring Abbreviation)
Long Form:   lipoprotein apheresis
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 A complicated pregnancy in homozygous familial hypercholesterolaemia treated with lipoprotein apheresis: A case report. HoFH, LDL-C, NSTEMI, TC
2019 A cross-national investigation of cardiovascular survival in homozygous familial hypercholesterolemia: The Sino-Roman Study. CVD, HoFH, LDL
2019 Actual situation of lipoprotein apheresis in patients with elevated lipoprotein(a) levels. GWAS, LDL-C
2019 Coronary computed tomography angiography and echocardiography in children with homozygous familial hypercholesterolemia. CCTA, HoFH, LDL-C
2019 Effect of evolocumab on lipoprotein apheresis requirement and lipid levels: Results of the randomized, controlled, open-label DE LAVAL study. LDL-C
2019 Efficacy and safety of lipoprotein apheresis in children with homozygous familial hypercholesterolemia: A systematic review. CVD, HoFH, LDL-C
2019 Experience with proprotein convertase subtilisin/kexine type 9 inhibitors (PCSK9i) in patients undergoing lipoprotein apheresis. LDL-C, PCSK9i
2019 Improvement of oxidative stress status by lipoprotein apheresis in Chinese patients with familial hypercholesterolemia. FH, FORD, FORT, OS
2019 Influence of lipoprotein apheresis on circulating plasma levels of miRNAs in patients with high Lp(a). miRNAs
10  2019 Lipoprotein apheresis efficacy, challenges and outcomes: A descriptive analysis from the UK Lipoprotein Apheresis Registry, 1989-2017. HeFH, HoFH, MACE
11  2019 Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease. CVD, LDL-C
12  2019 Lipoprotein apheresis in Germany - Still more commonly indicated than implemented. How can patients in need access therapy? CAD, CVD, LDL-C
13  2019 Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels. ASCVD, CVD, GLAR, LDL-C, MACE, MANCE
14  2019 Lipoprotein(a)-an interdisciplinary challenge. CVE, PCSK9
15  2019 Looking at Lp(a) and Related Cardiovascular Risk: from Scientific Evidence and Clinical Practice. EMA, HDL, LDL
16  2019 NMR-based lipoprotein analysis for patients with severe hypercholesterolemia undergoing lipoprotein apheresis or PCSK9-inhibitor therapy (NAPALI-Study). HDL-C, LDL-C, LDL-P, PCSK9
17  2019 Optical coherence tomography of retinal and choroidal layers in patients with familial hypercholesterolaemia treated with lipoprotein apheresis. BVCA, ChT, CMT, FAZ, FH, IOP, OCT, OCTA, SE, VD
18  2019 Pleiotropic Effect of Lipoprotein-Apheresis on the Soluble Form of Activated Leukocyte Cell Adhesion Molecule (sALCAM) in Familial Hypercholesterolaemia. ALCAM, LDL-C, PRR, sALCAM
19  2019 Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia. ASCVD, HoFH, LDL-C
20  2019 Real-world study: Escalating targeted lipid-lowering treatment with PCSK9-inhibitors and lipoprotein apheresis. ASCVD, LLT, PCSK9, TEAE
21  2019 Role of Lipoprotein Apheresis in Cardiovascular Disease Risk Reduction. CVD, FH
22  2019 Short- and long-term effects of lipoprotein apheresis on plasma hormones in patients with therapy-resistant dyslipidemia. DALI, DSA, LF, MONET
23  2018 A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry). HoFH, LDL-C
24  2018 Current Role of Lipoprotein Apheresis in the Treatment of High-Risk Patients. CVE
25  2018 High serum triglyceride concentrations in patients with homozygous familial hypercholesterolemia attenuate the efficacy of lipoprotein apheresis by dextran sulfate adsorption. DSA, HELP, HoFH
26  2018 Impact of lipoprotein apheresis with dextran-sulfate adsorption on the expression of genes involved in cardiovascular health in the blood of patients with homozygous familial hypercholesterolemia. BCL3, DSA, Egr, HoFH
27  2018 Improvement of refractory pruritus after lipoprotein-apheresis in arthrogryposis-renal failure-cholestasis syndrome. TBA
28  2018 Lipoprotein Apheresis and PCSK9-Inhibitors. Impact on Atherogenic Lipoproteins and Anti-Inflammatory Mediators in Familial Hypercholesterolaemia. HeFH, HoFH, PCSK9-I
29  2018 Lipoprotein-apheresis in familial hypercholesterolemia: Long-term patient compliance in a French cohort. ---
30  2018 Long-term lipoprotein apheresis in the treatment of severe familial hypercholesterolemia refractory to high intensity statin therapy: Three year experience at a lipoprotein apheresis centre. DALI, FH, HDL-C, HeFH, IAS, LDL-C, MONET, TC, TG
31  2018 Management of homozygous familial hypercholesterolaemia in two brothers. HoFH, LDL-C
32  2018 Multimodal lipid-lowering treatment in pediatric patients with homozygous familial hypercholesterolemia-target attainment requires further increase of intensity. chet, CVD, FH, HO, LDL-C, LLT, PCSK9
33  2018 Reduced incidence of cardiovascular events in hyper-Lp(a) patients on lipoprotein apheresis. The G.I.L.A. (Gruppo Interdisciplinare Aferesi Lipoproteica) pilot study. ACVE
34  2018 Treatment-related and health-related quality of life in lipoprotein apheresis patients. HRQOL, QOL
35  2018 Vascular access in lipoprotein apheresis: a retrospective analysis from the UK's largest lipoprotein apheresis centre. AV, LDL
36  2017 Barriers to the Implementation of Lipoprotein Apheresis in Canada. HoFH
37  2017 Case report of male child with elevated lipoprotein (a) leading to acute ischemic stroke. AIS
38  2017 Current insights into the German Lipoprotein Apheresis Registry (GLAR) - Almost 5 years on. CVD, GLAR, LDL-C
39  2017 Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both? PCSK9-I
40  2017 Dysregulation of the CD4+ T cells lineage differentiation in dyslipidemic patients and impact of lipoprotein-apheresis treatment: A case study. ---
41  2017 Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia: Results of a Real-World Clinical Experience in Italy. HoFH, LLT, MRS
42  2017 H.E.L.P apheresis exerts long term effects on the capacity of circulating proangiogenic cells. CV, HELP, PAC, SDF-1
43  2017 How effectively will PCSK9 inhibitors allow retrieval of freedom from apheresis in cardiovascular high risk patients? - Estimates form a large single center. LDL-C, PCSK-9
44  2017 Hyperlipoproteinaemia(a) - apheresis and emerging therapies. CVD, LDL-C
45  2017 Kinetics of Lipoprotein(a) in patients undergoing weekly lipoprotein apheresis for Lp(a) hyperlipoproteinemia. ---
46  2017 Lipoprotein apheresis downregulates IL-1alpha, IL-6 and TNF-alpha mRNA expression in severe dyslipidaemia. CAD, mRNA
47  2017 Lipoprotein apheresis in patients with peripheral artery disease and lipoprotein(a)-hyperlipoproteinemia: 2-year follow-up of a prospective single center study. ABI, PAD, VAS
48  2017 Lipoprotein apheresis influences monocyte subpopulations. ---
49  2017 Lipoprotein(a)-hyperlipoproteinemia as cause of chronic spinal cord ischemia resulting in progressive myelopathy - successful treatment with lipoprotein apheresis. CAD, CVD, PAOD
50  2017 Most significant reduction of cardiovascular events in patients undergoing lipoproteinapheresis due to raised Lp(a) levels - A multicenter observational study. CV
51  2017 Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines. CVD, HLP, MACE
52  2017 Prospective crossover study for a standardized comparison of the dextrane sulfate whole blood and plasma apheresis system in patients with cardiovascular disease and severe dyslipidemia. ---
53  2017 Rationale and design of MultiSELECt: A European Multicenter Study on the Effect of Lipoprotein(a) Elimination by lipoprotein apheresis on Cardiovascular outcomes. CVD, LDL-C
54  2017 The German Lipoprotein Apheresis Registry (GLAR) - almost 5years on. CVD, GLAR
55  2017 Toward an international consensus-Integrating lipoprotein apheresis and new lipid-lowering drugs. ---
56  2016 Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization. ---
57  2016 Lipoprotein apheresis in the management of severe hypercholesterolemia and of elevation of lipoprotein(a): current perspectives and patient selection. HCh, LDL-C
58  2016 Lipoprotein apheresis is essential for managing pregnancies in patients with homozygous familial hypercholesterolemia: Seven case series and discussion. HoFH
59  2016 Lipoprotein apheresis reduces circulating galectin-3 in humans. DSA, Gal-3, HELP
60  2016 Lipoprotein Apheresis. CVD, FH, LDL-C
61  2016 Long-Term Follow-Up of a Homozygous Familial Hypercholesterolemic Patient Receiving Regular Double Filtration Plasmapheresis - Case Report and Literature Review. DFPP, HoFH, LDL, LDL-C
62  2016 Management of homozygous familial hypercholesterolemia in real-world clinical practice: A report of 7 Italian patients treatedinRome with lomitapide and lipoproteinapheresis. AEs, HoFH, LDL-C
63  2016 Quality of life in patients treated with lipoprotein apheresis. BDI, CVD, LDL-C, QOL
64  2016 Ten years of lipoprotein apheresis for familial hypercholesterolemia in Malaysia: A creative approach by a cardiologist in a developing country. FH
65  2016 The role of lipoprotein(a) in clotting reactions during lipoprotein apheresis--A case report. FH
66  2016 Validation of a new method for non-invasive assessment of vasomotor function. COV, FH, FMD, FMS, PWV
67  2015 Actual situation of lipoprotein apheresis in Saxony in 2013. CVE, HoFH, non-HDL-C, TG, UHD
68  2015 Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease. CVD, LDL-C
69  2015 Detailed description of the cardiovascular situation in patients who have started lipoprotein apheresis treatment. CVE, LDL-C
70  2015 Effects of different lipoprotein apheresis methods on serum protein levels. ---
71  2015 Effects of lipoprotein apheresis on PCSK9 levels. LDL-C, LDLR
72  2015 Effects of Lipoprotein apheresis on the Lipoprotein(a) levels in the long run. ---
73  2015 Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany. AE, CVD, LDL-C, MACE
74  2015 Impact of the German Lipoprotein Apheresis Registry (DLAR) on therapeutic options to reduce increased Lp(a) levels. LDL-C, MACE, MANCE
75  2015 Increasing plasma lysophosphatidylcholine levels in patients with regular dextran sulfate lipoprotein apheresis. DSA, LPC, PE
76  2015 Lipoprotein apheresis for Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease--Additional particular aspects of the Pro(a)LiFe multicenter trial. CVD
77  2015 Lipoprotein apheresis in patients with peripheral artery disease and hyperlipoproteinemia(a). ABI, PAD
78  2015 Lipoprotein apheresis results in plaque stabilization and prevention of cardiovascular events: comments on the prospective Pro(a)LiFe study. HLP, LDL
79  2015 Lipoprotein apheresis. CVD, FH, LDL-C
80  2015 Mental symptoms and quality of life in lipoprotein apheresis patients in comparison to hemodialysis patients, platelet donors and normal population. CAQ, HADS, HD, HRQL, NP
81  2015 The incidence of cardiovascular events is largely reduced in patients with maximally tolerated drug therapy and lipoprotein apheresis. A single-center experience. ACVE, FCH, FH
82  2015 TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose. FCM, FG, ID, IDA
83  2015 Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide. HoFH, LDL-C, LLTs, MTP
84  2015 [Position of lipoprotein apheresis in present]. FH, LDL
85  2014 LDL-apheresis dramatically improves generalized calciphylaxis in a patient undergoing hemodialysis. SPP
86  2014 Lipoprotein apheresis reduces biomarkers of plaque destabilization and cardiovascular risk. ---
87  2013 How to optimize lipoprotein apheresis treatment--a second look. BV, LDL-C
88  2013 Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. ---
89  2013 Lipoprotein apheresis: state of the art and novelties. CVR, LDL, PEX
90  2013 Loss of plasma proprotein convertase subtilisin/kexin 9 (PCSK9) after lipoprotein apheresis. FH, LDL, PCSK9
91  2004 Impact of regular LDL apheresis on the development of restless legs syndrome. RLS
92  0 The role of PCSK9-inhibitors and of lipoprotein apheresis in the treatment of homozygous and severe heterozygous familial hypercholesterolemia: A rivalry, or are things quite different? FH, LDL, LDL-C, PCSK9